NASDAQ:MITO

Stealth BioTherapeutics Stock Forecast, Price & News

$1.38

0.00 (0.00 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.35

▼

$1.40

50-Day Range

$1.31

▼

$1.77

52-Week Range

$1.06

▼

$2.58

Volume45,435 shs

Average Volume158,055 shs

Market Capitalization$78.72 million

P/E RatioN/A

Dividend YieldN/A

Beta2.04

30 days | 90 days | 365 days | Advanced Chart

Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Stealth BioTherapeutics to Report Second Quarter Financial Results on Thursday, August 5
July 30, 2021 | finance.yahoo.com

Stealth BioTherapeutics Corp (NASDAQ:MITO) Short Interest Update
July 28, 2021 | americanbankingnews.com

Brokerages Anticipate Stealth BioTherapeutics Corp (NASDAQ:MITO) Will Announce Earnings of -$0.02 Per Share
July 24, 2021 | americanbankingnews.com

Stealth BioTherapeutics Corp (NASDAQ:MITO) Sees Significant Growth in Short Interest
July 15, 2021 | americanbankingnews.com

Stealth BioTherapeutics (MITO) Sees Hammer Chart Pattern: Time to Buy?
July 8, 2021 | finance.yahoo.com

Stealth BioTherapeutics Joins the Rare Disease Company Coalition
July 7, 2021 | finance.yahoo.com

Comparing Lannett (NYSE:LCI) & Stealth BioTherapeutics (NASDAQ:MITO)
July 7, 2021 | americanbankingnews.com

Stealth BioTherapeutics' (NASDAQ:MITO) Shareholders Are Down 19% On Their Shares
July 6, 2021 | nasdaq.com

Stealth BioTherapeutics'(NASDAQ:MITO) Share Price Is Down 19% Over The Past Year.
July 6, 2021 | finance.yahoo.com

Is MITO Stock A Buy Here?
June 18, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MITO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.stealthbt.com
Phone617-600-6888
Employees29
Year FoundedN/A

Sales & Book Value

Annual Sales$21.09 million
Price / Sales3.73
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.20) per share
Price / Book-6.90

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-57,460,000.00
Net MarginsN/A
Return on Equity-3,886.17%
Return on Assets-156.45%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares57,040,000
Market Cap$78.72 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.55 out of 5 stars

Medical Sector

1076th out of 2,220 stocks

Pharmaceutical Preparations Industry

506th out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
Stealth BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Stealth BioTherapeutics has a forecasted upside of 117.4% from its current price of $1.38.
Amount of Analyst Coverage
Stealth BioTherapeutics has only been the subject of 2 research reports in the past 90 days.

4.3 Community Rank

Outperform Votes
Stealth BioTherapeutics has received 78 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Stealth BioTherapeutics has received 44 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Stealth BioTherapeutics has received 63.93% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote “Outperform” if you believe MITO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Stealth BioTherapeutics does not currently pay a dividend.
Dividend Growth
Stealth BioTherapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stealth BioTherapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 4.46% of the stock of Stealth BioTherapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Stealth BioTherapeutics are expected to decrease in the coming year, from ($0.06) to ($0.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stealth BioTherapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stealth BioTherapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

Is Stealth BioTherapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Stealth BioTherapeutics stock.
View analyst ratings for Stealth BioTherapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Stealth BioTherapeutics?

Wall Street analysts have given Stealth BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Stealth BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Stealth BioTherapeutics?

Stealth BioTherapeutics saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 86,700 shares, a drop of 73.2% from the June 30th total of 323,400 shares. Based on an average daily trading volume, of 5,250,000 shares, the days-to-cover ratio is currently 0.0 days.
View Stealth BioTherapeutics' Short Interest.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Stealth BioTherapeutics.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its earnings results on Tuesday, May, 18th. The company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.01.
View Stealth BioTherapeutics' earnings history.

How has Stealth BioTherapeutics' stock been impacted by Coronavirus?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MITO stock has decreased by 13.1% and is now trading at $1.38.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MITO?

2 equities research analysts have issued 1 year price targets for Stealth BioTherapeutics' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Stealth BioTherapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 117.4% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics or view top-rated stocks among Wall Street analysts.

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:

Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 57)
Mr. Robert J. Weiskopf, Chief Financial Officer (Age 70)
Mr. Henry Hess, Chief Legal Counsel
Mr. Mike Malynn, VP of HR
Dr. Ben R. Bronstein, Chief Medical Officer (Age 71)
Dr. Brian D. Blakey, Chief Bus. Officer (Age 59)
Dr. W. Douglas Weaver, Chief Medical Officer
Mr. James R. Carr, Chief Clinical Devel. Officer (Age 58)
Dr. Marty P. Redmon Ph.D., Chief R&D Officer (Age 59)

Who are some of Stealth BioTherapeutics' key competitors?

Some companies that are related to Stealth BioTherapeutics include 89bio (ETNB), Impel NeuroPharma (IMPL), MEI Pharma (MEIP), Puma Biotechnology (PBYI), PDS Biotechnology (PDSB), Fortress Biotech (FBIO), Aeglea BioTherapeutics (AGLE), RedHill Biopharma (RDHL), Aerovate Therapeutics (AVTE), Flexion Therapeutics (FLXN), Neoleukin Therapeutics (NLTX), Verrica Pharmaceuticals (VRCA), Taiwan Liposome (TLC), Millendo Therapeutics (MLND) and Syros Pharmaceuticals (SYRS).
View all of MITO's competitors.

What other stocks do shareholders of Stealth BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), Soleno Therapeutics (SLNO) and Arbutus Biopharma (ABUS).

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $1.38.

How much money does Stealth BioTherapeutics make?

Stealth BioTherapeutics has a market capitalization of $78.72 million and generates $21.09 million in revenue each year. The company earns $-57,460,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How many employees does Stealth BioTherapeutics have?

Stealth BioTherapeutics employs 29 workers across the globe.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is www.stealthbt.com.

Where are Stealth BioTherapeutics' headquarters?

Stealth BioTherapeutics is headquartered at 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here